---
title: "U.S. stock market midday update: CRISPR Therap up 7.25%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247863133.md"
description: "CRISPR Therap rose 7.25%; ProKidney rose 25.16%, with a transaction volume of USD 1.075 billion; Calidi Biotherapeutics rose 232.87%, with a transaction volume of USD 561 million; Abbvie fell 0.12%, with a transaction volume of USD 331 million, and a market capitalization of USD 334.8 billion"
datetime: "2025-07-09T17:07:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247863133.md)
  - [en](https://longbridge.com/en/news/247863133.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247863133.md)
generator: "portal-rs"
---

# U.S. stock market midday update: CRISPR Therap up 7.25%

**U.S. Stock Market Midday Update**

CRISPR Therap, up 7.25%, with increased trading volume. Based on recent important news:

1.  On July 8, Chan Zuckerberg Initiative and Innovative Genomics Institute announced funding for the progress of personalized CRISPR Therap. This news boosted market confidence, driving CRISPR Therap's stock price up 7.25%.

**Top Stocks by Industry Trading Volume**

ProKidney up 25.16%, with a trading volume of 1.075 billion. Based on recent important news:

1.  On July 8, ProKidney announced positive results from its REGEN-007 trial, showing that Rilparencel significantly improved eGFR slope in chronic kidney disease patients, leading to a 25% increase in stock price.

2.  On July 9, the FDA confirmed that it would consider accelerated approval if Phase 3 trial results are similar, with optimistic market sentiment driving the stock price further up.

3.  On July 10, Citigroup raised ProKidney's target price from $6 to $9, further stimulating the stock price increase.

Calidi Biotherapeutics up 232.87%. Based on recent key news:

1.  On July 8, Calidi Biotherapeutics announced its mention in an editorial by NetworkNewsWire, increasing market attention to its brand, resulting in a significant stock price surge.

2.  Over the past 5 days, Calidi Biotherapeutics' stock price has cumulatively risen by 384.83%, showing strong investor confidence in its future development.

3.  Recent trading volume reached $561 million, indicating a significant increase in market interest in the company.

Abbvie down 0.12%, with increased trading volume. Based on recent important news:

1.  On July 9, analysts noted that Abbvie was not on the recommended list, despite a moderate buy rating, leading to pressure on the stock price.

2.  On July 9, increased volatility in the innovative drug industry and turmoil in overseas markets affected investor confidence, causing Abbvie's stock price to decline.

3.  On July 7, progress in CAR-T cell therapy in the field of autoimmune diseases failed to boost Abbvie's stock price.

**Top Stocks by Industry Market Capitalization**

Abbvie down 0.12%, with increased trading volume. Based on recent important news:

1.  On July 9, analysts noted that Abbvie was not on the recommended buy list, despite its moderate buy rating, leading to insufficient market confidence and a decline in stock price.

2.  On July 9, high volatility in the innovative drug industry and investor bias affected market sentiment, leading to stock price fluctuations On July 7th, the application prospects of CAR-T cell therapy in autoimmune diseases attracted market attention, but failed to boost Abbvie's stock price

### Related Stocks

- [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md)
- [PROK.US](https://longbridge.com/en/quote/PROK.US.md)
- [CLDI.US](https://longbridge.com/en/quote/CLDI.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [US inflation rises below expectations in August, gives the Fed breathing space](https://longbridge.com/en/news/300635276.md)
- [Nike Q1 Preview: Stock at 13-Year Lows, Market Expert Finds Bright Spot for Bulls](https://longbridge.com/en/news/300600878.md)
- ['On to the Next Big Piece,' Says Top Investor About Rocket Lab Stock](https://longbridge.com/en/news/300592979.md)
- [McDonald’s Stock Forecast: AI Pricing and $8.5 Billion Plan Test MCD’s Recovery](https://longbridge.com/en/news/300591685.md)
- [McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier](https://longbridge.com/en/news/300606178.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**